Printer Friendly

AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.

Tokyo, Japan, Oct 4, 2005 - (JCNN) - AnGes MG has commenced a phase I clinical trial of NF-kappa B decoy oligodeoxynucleotide. The clinical trial aims to seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the treatment of atopic dermatitis.

The company has partnered with Alfresa Pharma in the trial. Currently, there are over 1.4 million people with atopic dermatitis in Japan, and no effective treatment for severe atopic dermatitis has yet to be established.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 5, 2005
Words:91
Previous Article:ESPEC Releases Carbon Dioxide Incubator with Dry-Heat Sterilizing Function.
Next Article:JVC Develops Base Technologies for Next-generation Optical Wireless Access System.


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |